{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T16:38:21Z","timestamp":1782923901987,"version":"3.54.5"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience Letters"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.neulet.2021.136202","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T12:05:36Z","timestamp":1630411536000},"page":"136202","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["PARP inhibitor PJ34 ameliorates cognitive impairments induced by transient cerebral ischemia\/reperfusion through its anti-inflammatory effects in a rat model"],"prefix":"10.1016","volume":"764","author":[{"given":"Yong","family":"Jiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.neulet.2021.136202_b0005","doi-asserted-by":"crossref","first-page":"566","DOI":"10.2353\/ajpath.2006.051066","article-title":"Cerebral ischemia-hypoxia induces intravascular coagulation and autophagy","volume":"169","author":"Adhami","year":"2006","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.neulet.2021.136202_b0010","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.biochi.2010.09.009","article-title":"Targeting cyclooxygenases-1 and -2 in neuroinflammation: Therapeutic implications","volume":"93","author":"Aid","year":"2011","journal-title":"Biochimie"},{"issue":"3","key":"10.1016\/j.neulet.2021.136202_b0015","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.ajpath.2010.12.004","article-title":"Signaling mechanism of poly(ADP-ribose) polymerase-1 (PARP-1) in inflammatory diseases","volume":"178","author":"Ba","year":"2011","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.neulet.2021.136202_b0020","first-page":"640","article-title":"Poly(ADP-ribose) polymerase-1 and its cleavage products differentially modulate cellular protection through NF-kappaB-dependent signaling","volume":"2014","author":"Castri","year":"1843","journal-title":"BBA"},{"issue":"6","key":"10.1016\/j.neulet.2021.136202_b0025","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/14656566.2017.1309022","article-title":"Current and future perspectives on the treatment of cerebral ischemia","volume":"18","author":"Christophe","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"issue":"8","key":"10.1016\/j.neulet.2021.136202_b0030","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"10.1016\/j.neulet.2021.136202_b0035","doi-asserted-by":"crossref","first-page":"9156","DOI":"10.1007\/s12035-018-1063-3","article-title":"Improved Reperfusion and Vasculoprotection by the Poly(ADP-Ribose)Polymerase Inhibitor PJ34 After Stroke and Thrombolysis in Mice","volume":"55","author":"El Amki","year":"2018","journal-title":"Mol. Neurobiol."},{"issue":"3","key":"10.1016\/j.neulet.2021.136202_b0040","doi-asserted-by":"crossref","first-page":"e89450","DOI":"10.1371\/journal.pone.0089450","article-title":"Protective effect of glycyrrhizin, a direct HMGB1 inhibitor, on focal cerebral ischemia\/reperfusion-induced inflammation, oxidative stress, and apoptosis in rats","volume":"9","author":"Gong","year":"2014","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.neulet.2021.136202_b0045","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1517\/14728222.12.2.159","article-title":"Tissue-type plasminogen activator as a therapeutic target in stroke","volume":"12","author":"Gravanis","year":"2008","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.neulet.2021.136202_b0050","doi-asserted-by":"crossref","unstructured":"M. Haddad, V. Beray-Berthat, B. Coqueran, M. Plotkine, C. Marchand-Leroux, I. Margaill, Combined therapy with PJ34, a poly(ADP-ribose)polymerase inhibitor, reduces tissue plasminogen activator-induced hemorrhagic transformations in cerebral ischemia in mice, Fundam Clin Pharmacol 27 (2013) 393-401.","DOI":"10.1111\/j.1472-8206.2012.01036.x"},{"issue":"2","key":"10.1016\/j.neulet.2021.136202_b0055","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1161\/01.STR.0000250742.61241.79","article-title":"Use of a poly(ADP-ribose) polymerase inhibitor to suppress inflammation and neuronal death after cerebral ischemia-reperfusion","volume":"38","author":"Hamby","year":"2007","journal-title":"Stroke"},{"key":"10.1016\/j.neulet.2021.136202_b0060","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s12012-018-9462-2","article-title":"Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders","volume":"18","author":"Henning","year":"2018","journal-title":"Cardiovasc. Toxicol."},{"issue":"1-2","key":"10.1016\/j.neulet.2021.136202_b0065","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0027-5107(01)00111-7","article-title":"Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death","volume":"477","author":"Herceg","year":"2001","journal-title":"Mutat. Res."},{"issue":"3","key":"10.1016\/j.neulet.2021.136202_b0070","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.37175\/stemedicine.v1i3.59","article-title":"Inflammatory events drive neural stem cell migration by elevating stromal-derived factor 1 alpha","volume":"1","author":"Jiang","year":"2020","journal-title":"STEMedicine"},{"key":"10.1016\/j.neulet.2021.136202_b0075","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/B978-0-12-394309-5.00006-7","article-title":"Cell biology of ischemia\/reperfusion injury","volume":"298","author":"Kalogeris","year":"2012","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"10.1016\/j.neulet.2021.136202_b0080","doi-asserted-by":"crossref","unstructured":"L. L, W. X, Y. Z, Ischemia-reperfusion Injury in the Brain: Mechanisms and Potential Therapeutic Strategies, Biochem Pharmacol (Los Angel) 5 (2016).","DOI":"10.4172\/2167-0501.1000213"},{"issue":"3","key":"10.1016\/j.neulet.2021.136202_b0085","doi-asserted-by":"crossref","first-page":"373","DOI":"10.4103\/1673-5374.228711","article-title":"Cerebral ischemia and neuroregeneration","volume":"13","author":"Lee","year":"2018","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.neulet.2021.136202_b0090","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1476-9255-7-27","article-title":"Anti-inflammatory treatment strategies for ischemia\/reperfusion injury in transplantation","volume":"7","author":"Lutz","year":"2010","journal-title":"J. Inflamm. (Lond.)"},{"key":"10.1016\/j.neulet.2021.136202_b0095","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/321653","article-title":"Pleiotropic cellular functions of PARP1 in longevity and aging: genome maintenance meets inflammation","volume":"2012","author":"Mangerich","year":"2012","journal-title":"Oxid. Med. Cell Longev."},{"key":"10.1016\/j.neulet.2021.136202_b0100","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.brainres.2011.05.069","article-title":"MP-124, a novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor, ameliorates ischemic brain damage in a non-human primate model","volume":"1410","author":"Matsuura","year":"2011","journal-title":"Brain Res."},{"issue":"18","key":"10.1016\/j.neulet.2021.136202_b0105","doi-asserted-by":"crossref","first-page":"10966","DOI":"10.1073\/pnas.95.18.10966","article-title":"Interaction between inducible nitric oxide synthase and cyclooxygenase-2 after cerebral ischemia","volume":"95","author":"Nogawa","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neulet.2021.136202_b0110","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1093\/emboj\/18.16.4446","article-title":"Resistance to endotoxic shock as a consequence of defective NF-kappaB activation in poly (ADP-ribose) polymerase-1 deficient mice","volume":"18","author":"Oliver","year":"1999","journal-title":"EMBO J."},{"issue":"3","key":"10.1016\/j.neulet.2021.136202_b0115","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1527-3466.2007.00018.x","article-title":"Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors","volume":"25","author":"Pacher","year":"2007","journal-title":"Cardiovasc. Drug Rev."},{"key":"10.1016\/j.neulet.2021.136202_b0120","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00234-006-0183-z","article-title":"Reperfusion injury following cerebral ischemia: pathophysiology, MR imaging, and potential therapies","volume":"49","author":"Pan","year":"2007","journal-title":"Neuroradiology"},{"issue":"1","key":"10.1016\/j.neulet.2021.136202_b0125","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/cells9010041","article-title":"Multifaceted Role of PARP-1 in DNA Repair and Inflammation: Pathological and Therapeutic Implications in Cancer and Non-Cancer Diseases","volume":"9","author":"Pazzaglia","year":"2019","journal-title":"Cells"},{"issue":"7","key":"10.1016\/j.neulet.2021.136202_b0130","doi-asserted-by":"crossref","first-page":"R473","DOI":"10.1152\/ajpregu.00355.2012","article-title":"Reciprocal regulation of the nitric oxide and cyclooxygenase pathway in pathophysiology: relevance and clinical implications","volume":"304","author":"Salvemini","year":"2013","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"issue":"5","key":"10.1016\/j.neulet.2021.136202_b0135","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1747-4949.2012.00916.x","article-title":"A comparative study of neuroprotective effect of single and combined blockade of AT1 receptor and PARP-1 in focal cerebral ischaemia in rat","volume":"9","author":"Singh","year":"2014","journal-title":"Int. J. Stroke"},{"key":"10.1016\/j.neulet.2021.136202_b0140","doi-asserted-by":"crossref","first-page":"138","DOI":"10.2174\/157340310791658785","article-title":"Epidemiology and risk factors of cerebral ischemia and ischemic heart diseases: similarities and differences","volume":"6","author":"Soler","year":"2010","journal-title":"Curr. Cardiol. Rev."},{"issue":"6","key":"10.1016\/j.neulet.2021.136202_b0145","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.bcp.2009.04.029","article-title":"Inflammatory cytokines in vascular dysfunction and vascular disease","volume":"78","author":"Sprague","year":"2009","journal-title":"Biochem. Pharmacol."},{"issue":"8","key":"10.1016\/j.neulet.2021.136202_b0150","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1089\/neu.2013.3194","article-title":"PARP-1 inhibition attenuates neuronal loss, microglia activation and neurological deficits after traumatic brain injury","volume":"31","author":"Stoica","year":"2014","journal-title":"J. Neurotrauma"},{"issue":"6","key":"10.1016\/j.neulet.2021.136202_b0155","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/FJC.0b013e3181faeaf0","article-title":"Minocycline protects cardiac myocytes against simulated ischemia-reperfusion injury by inhibiting poly(ADP-ribose) polymerase-1","volume":"56","author":"Tao","year":"2010","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.neulet.2021.136202_b0160","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.2147\/DDDT.S67655","article-title":"Studies of selective TNF inhibitors in the treatment of brain injury from stroke and trauma: a review of the evidence to date","volume":"8","author":"Tuttolomondo","year":"2014","journal-title":"Drug Des. Devel. Ther."},{"issue":"5","key":"10.1016\/j.neulet.2021.136202_b0165","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1747-4949.2012.00839.x","article-title":"Pathophysiologic cascades in ischemic stroke","volume":"7","author":"Xing","year":"2012","journal-title":"Int. J. Stroke"},{"key":"10.1016\/j.neulet.2021.136202_b0170","first-page":"199","article-title":"Schizandrin A protects against cerebral ischemia-reperfusion injury by suppressing inflammation and oxidative stress and regulating the AMPK\/Nrf2 pathway regulation","volume":"11","author":"Zhou","year":"2019","journal-title":"Am. J. Transl. Res."}],"container-title":["Neuroscience Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394021005802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304394021005802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T20:42:19Z","timestamp":1759610539000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304394021005802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":34,"alternative-id":["S0304394021005802"],"URL":"https:\/\/doi.org\/10.1016\/j.neulet.2021.136202","relation":{},"ISSN":["0304-3940"],"issn-type":[{"value":"0304-3940","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PARP inhibitor PJ34 ameliorates cognitive impairments induced by transient cerebral ischemia\/reperfusion through its anti-inflammatory effects in a rat model","name":"articletitle","label":"Article Title"},{"value":"Neuroscience Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neulet.2021.136202","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"136202"}}